Comment: Pharma deal could be difficult to swallow
Big pharma deal could be
difficult one to swallow
FIRST it was the banks, then the energy companies. Now it’s the pharmaceuticals industry that the public loves to hate.
Opposition comes in many guises, but it is essentially an issue of size. No-one seems to love a company that gets too big, and the proposed acquisition by US-based Pfizer of AstraZeneca is the mother of all deals. At £63 billion, it would be the biggest takeover of a British company by a foreign firm.
Advertisement
Hide AdAdvertisement
Hide Ad